Abstract:Transforming growth factor-β (TGF-β), an important cytokine that plays a key role in many diseases regulates a wide array of cellular and physiologic processes via several TGF-β-driven signaling cascades, including the SMAD and non-SMAD-driven pathways. However, the detailed mechanisms by which TGF-β induces such diverse responses remain poorly understood. In particular, compared to the SMAD-dependent pathway, SMAD-independent pathways such as the ERK/MAPK pathway, which is critical in cancer progression, are less characterized. Here, we develop an integrated mechanistic model of the TGF-β-triggered ERK activation pathway and its crosstalk with the SMAD pathway, an analysis of which demonstrates how SMAD dynamics can be significantly modulated and regulated by the ERK pathway. In particular, SMAD-mediated transcription can be altered and delayed due to expedited phosphorylation of the linker of SMAD by TGF-β-activated ERK; and enhanced ERK activity, but attenuated SMAD activity, can be achieved simultaneously by fast turnover of TGF-β receptors via lipid-rafts. Also, in silico mutations of the TGF-β pathways reveal that the dynamic characteristics of both SMAD and ERK signaling may change significantly during cancer development. Specifically, normal cells may exhibit enhanced and sustained SMAD signaling with transient ERK activation, whereas cancerous cells may produce elevated and prolonged ERK signaling with enervated SMAD activation. These distinctive differences between normal and cancerous signaling behavior provide clues concerning, and potential explanations for, the seemingly contradictory roles played by TGF-β during cancer progression. We demonstrate how crosstalk among various branch pathways of TGF-β can influence overall cellular behavior. Based on model analysis, we hypothesize that aberrant molecular alterations drive changes in the intensity and duration of SMAD and ERK signaling during cancer progression and ultimately lead to an imbalance between the SMAD and ERK pathways in favor of tumor promotion. Thus, to treat cancer patients with a genetic signature of oncogenic Ras effectively may require at least a combination therapy to restore both the expression of TGF-β receptors and the GTPase activity of Ras.

Disruption of the transforming growth factor-β pathway by tolfenamic acid via the ERK MAP kinase pathway.

The involvement of lipid raft pathway in suppression of TGFβ-mediated metastasis by tolfenamic acid in hepatocellular carcinoma cells.

Curcumin Inhibits Transforming Growth Factor-Beta Activity Via Inhibition of Smad Signaling in HK-2 Cells.

Abstract LB-181: Tolfenamic Acid Suppresses Intestinal Tumorigenesis Through Inhibiting Cyclin D1 Translation.

The Involvement of Endoplasmic Reticulum Stress in the Suppression of Colorectal Tumorigenesis by Tolfenamic Acid

Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways

TACE-Mediated Ectodomain Shedding of the Type I TGF-b Receptor Downregulates TGF-b Signaling

TACE-Mediated Ectodomain Shedding of the Type I TGF-β Receptor Downregulates TGF-β Signaling

Supplementary Figures 1 - 3 from the Involvement of Endoplasmic Reticulum Stress in the Suppression of Colorectal Tumorigenesis by Tolfenamic Acid

Effect of TGF-beta 1 on apoptosis of colon cancer cells via the ERK signaling pathway

Positive and Negative Effects of TGF-β Signaling Pathways in Carcinogenesis

Computational Modeling and Analysis of the TGF-β-induced ERK and SMAD Pathways

Transforming Growth Factor Beta Signaling Pathway: A Promising Therapeutic Target For Cancer

Targeting TGF-β Signaling in Cancer.

Novel therapies emerging in oncology to target the TGF-β pathway

Tannic Acid Inhibits Proliferation, Migration, Invasion of Prostate Cancer and Modulates Drug Metabolizing and Antioxidant Enzymes

Curcumin Inhibits Transforming Growth Factor-Beta 1-Induced Emt Via Ppar Gamma Pathway, Not Smad Pathway In Renal Tubular Epithelial Cells

Transforming Growth Factor Β Signaling Pathway: A Promising Therapeutic Target for Cancer

The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target

Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy

Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy